Ipsen provides update on Phase III BOLD trial in biliary atresia
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and comple
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and complex condition, BA is the leading cause of paediatric liver transplant, with no approved therapeutic options beyond Kasai HPE or liver transplant surgery.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.